A biosafe skin lightening agent based on lysine synergistic system and method

Abstract

The application belongs to the technical field of biomedical optical imaging, and more particularly relates to a biosafe skin optical clearing agent and method based on a lysine synergistic system. The biosafe skin optical clearing agent provided in the application contains lysine or a salt thereof as an active ingredient, can effectively reduce the light scattering of skin tissue, and thus realizes the optical clearing of skin, and meanwhile, the morphology of the skin tissue is well maintained during the treatment. The skin optical clearing agent has the advantages of simple active ingredient, high biosafety, remarkable skin optical clearing effect, convenient preparation, simple application operation and the like, and is suitable for the optical clearing treatment of ex vivo skin and in vivo skin.

Description

Technical Field

[0001] This application belongs to the field of biomedical optical imaging technology, and more specifically, relates to a biosafe skin light-transmitting agent and method based on a lysine synergistic system. Background Technology

[0002] Achieving high-resolution deep imaging of living / ex vivo skin tissue is a key challenge in fields such as biomedical optical imaging, non-invasive dermatological detection, and photodynamic therapy. Due to its multi-scale internal structure and the non-uniform refractive index of its components, skin tissue exhibits strong scattering of incident light, severely limiting the penetration depth of light. This results in poor image quality and limited information acquisition, impacting the application of optical imaging, vascular observation, and phototherapy in the skin.

[0003] To address this issue, existing technologies propose methods for achieving light transparency in skin tissue. Currently, the light-transparent agents used in in vivo or ex vivo skin transparency techniques mainly include polyhydroxy small molecule sugar alcohols, high molecular weight hydrophilic polymers, organic acids, and organic solvents. Polyhydroxy small molecule sugar alcohols (such as glycerol and sucrose) typically achieve refractive index matching by replacing tissue water, but this process is often accompanied by significant dehydration, easily causing skin tissue contraction and morphological changes. High molecular weight hydrophilic polymers and organic acid agents (such as hyaluronic acid) have limited spontaneous transdermal penetration due to their large molecular weight, requiring a long time (usually more than 60 minutes) to achieve skin transparency. Organic solvent agents (such as dimethyl sulfoxide) have strong transdermal capabilities, but their lipolysis and protein denaturation effects may damage the stratum corneum structure, causing irreversible damage to the skin barrier. Furthermore, most existing light-transparent agents are exogenous chemical substances, and their penetration into the skin at high concentrations may pose certain biosafety risks.

[0004] In the field of skin cosmetics, technologies for improving skin appearance also exist. For example, patent application CN119947698A discloses the use of polylysine to combat protein carbonylation, addressing skin aging issues (such as decreased water retention, dullness, yellowing, and reduced skin transparency, elasticity, and contrast). It must be clearly stated that skin transparency in this field refers to a consumer-perceived description of skin texture. This relies on the high molecular weight characteristics of lysine to reduce and / or inhibit protein carbonylation on the skin through biochemical pathways, protecting it from carbonylation stimulation and thus repairing the skin barrier to improve skin appearance or mitigate skin aging. It does not, however, involve physically reducing light scattering within skin tissue to enhance light penetration.

[0005] In summary, there is an urgent need in this field for a skin light-transmitting agent that is simple in composition, has high biosafety, is easy to use, and can ensure biocompatibility and skin structure stability. Summary of the Invention

[0006] In view of the shortcomings of the prior art, the purpose of this application is to provide a biosafe skin light-transparency agent and method based on a lysine synergistic system, which aims to solve the problems of existing skin light-transparency agents having complex components, poor light-transparency effect on the skin, and affecting the morphology of skin tissue, and even causing damage to the skin barrier.

[0007] To achieve the above objectives, in a first aspect, this application provides a biosafe skin light-transmitting agent containing lysine or its salt as an active ingredient.

[0008] Preferably, the lysine mentioned above is L-lysine.

[0009] Preferably, the salt is a hydrochloride, acetate, or aspartate.

[0010] Preferably, the concentration of lysine or its salt in the above-mentioned skin-transparent agent is not less than 30% (w / v). More preferably, the concentration of lysine or its salt in the above-mentioned skin-transparent agent is 30% to 50% (w / v).

[0011] Preferably, the above-mentioned skin light-transparency agent further includes a functional synergistic component; wherein the above-mentioned functional synergistic component is selected from one or more of a penetration enhancer, a water-retaining agent, and a synergistic light-transparency agent.

[0012] Preferably, the penetration enhancer is selected from one or more of dimethyl sulfoxide, propylene glycol, and butylene glycol; the water-retaining agent is selected from one or more of glycerin, hyaluronic acid, urea, and hydrophilic polysaccharides; and the synergistic clearing agent is selected from one or more of iohexol, sorbitol, and polyethylene glycol.

[0013] Preferably, the concentration of the functional synergistic component in the above-mentioned skin light-transparency agent is 1% (w / v) to 15% (w / v).

[0014] Secondly, this application provides the application of the above-mentioned skin light-transparent agent in long-term transparentness of living skin, fluorescent labeling of isolated skin tissue cells, and preparation of drugs for adjuvant photodynamic therapy.

[0015] Thirdly, this application provides a method for optically transparentizing living skin tissue, comprising the following steps: The above-mentioned skin light-transparency agent was applied to bare skin tissue, and after standing, light-transparent skin tissue was obtained.

[0016] Preferably, the above-described method for phototransparency of living skin tissue further includes imaging the phototransparentized skin tissue.

[0017] In summary, the technical solutions conceived in this application have the following main technical advantages compared with the prior art: (1) The biosafe skin light-transparency agent provided in this application uses lysine or its salt as the active ingredient, and for the first time reveals and verifies that lysine or its salt has excellent skin light-transparency effect. This skin light-transparency agent enhances light penetration ability by effectively reducing light scattering of skin tissue, thereby significantly improving the light transparency of skin tissue, and can well maintain the original morphology of skin tissue during the treatment process. When applied to optical imaging, it can significantly improve imaging depth and signal-to-noise ratio.

[0018] (2) Compared with existing skin light-transparency agents, the skin light-transparency agent provided in this application has a single active ingredient, which does not require complex multi-component compounding, greatly simplifies the light-transparency agent formulation and makes preparation convenient; at the same time, the active ingredient itself has good biocompatibility, and does not need to rely on or introduce synthetic pigments or other substances that may pose a biosafety risk, thus providing a safety guarantee for long-term, repetitive optical imaging or monitoring of living skin.

[0019] (3) The skin light-transparency agent provided in this application can be applied in a "one-step" manner (such as a single application or soaking), avoiding the cumbersome process of using different components sequentially in the prior art. In addition, its dosage form can be flexibly formulated into various dosage forms such as aqueous solution, gel, and cream, which can be used for rapid light-transparency treatment of ex vivo skin tissue, as well as for non-invasive and reversible light-transparency of living skin, with a wide range of application scenarios.

[0020] (4) The skin light-transparent agent provided in this application has a synergistic effect with the water-retaining agent component. It can not only alleviate or inhibit the dehydration of skin tissue during the action of lysine or its salt, but also further enhance the light-transparent effect of skin tissue, effectively shortening the time for skin tissue to achieve complete light transparency. Attached Figure Description

[0021] Figure 1 This is a phototransparency effect diagram of isolated skin after phototransparency treatment with L-lysine aqueous solutions of different concentrations in Example 1 of this application, placed on a scale plate; Figure 2 This is an image of the light-transparency effect of isolated skin after being treated with L-lysine aqueous solutions of different concentrations in Example 1 of this application and then placed on a resolution plate. Figure 3 This is a resolution image of the isolated skin after phototransparency treatment with L-lysine aqueous solutions of different concentrations in Example 1 of this application; Figure 4 This is a comparison example 1 of this application, which shows the effect of phototransparency treatment of ex vivo skin using glycerin, sucrose, and hyaluronic acid; wherein content (a) is a photo of the ex vivo skin obtained by phototransparency treatment placed on a resolution plate, and content (b) is a resolution image of the ex vivo skin obtained by phototransparency treatment. Figure 5 This is a schematic diagram illustrating the effect of the skin light-transparency agent based on the lysine-water-retaining synergistic system provided in Embodiment 2 of this application on the light-transparency treatment of isolated skin; Figure 6 This is a schematic diagram illustrating the effect of using an L-lysine aqueous solution with a mass-volume ratio concentration of 35% (w / v) to perform phototransparency treatment on living skin in Example 3 of this application. Detailed Implementation

[0022] To make the objectives, technical solutions, and advantages of this application clearer, the following detailed description is provided in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of this application.

[0023] In the description of this application, it should be understood that the term "and / or" describes a relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, or B existing alone. The symbol " / " in this document indicates that the related objects are in an "or" relationship; for example, A / B means A or B.

[0024] In the description of the embodiments in this application, the words "exemplary" or "for example" are used to indicate that they are examples, illustrations, or descriptions. Any embodiment or design that is described as "exemplary" or "for example" in the embodiments of this application should not be construed as being more preferred or advantageous than other embodiments or design options. Specifically, the use of the words "exemplary" or "for example" is intended to present the relevant concepts in a specific manner.

[0025] In the description of the embodiments in this application, unless otherwise stated, "multiple" means two or more.

[0026] This application provides a biosafe skin light-transparency agent containing lysine or its salt as an active ingredient.

[0027] In some embodiments, the lysine mentioned above is L-lysine.

[0028] In some embodiments, the salt is a hydrochloride, acetate, or aspartate.

[0029] The inventors of this application unexpectedly discovered that lysine or its salts, when used as active ingredients in skin light-transparency agents, can exert a significant skin light-transparency effect. The reasons for this are likely twofold: first, after L-lysine molecules enter the dermis, they interact with the charged or polar groups on the surface of collagen molecules through their positively charged side-chain groups, thereby affecting the spatial arrangement of collagen fibers and reducing interfiber gaps; second, L-lysine solutions displace or rearrange some free water in skin tissue, making the refractive index distribution within the tissue more uniform. Through these synergistic effects, rather than relying on lysine-dependent polymerization or macromolecular interactions, the light scattering intensity within the skin tissue is reduced, macroscopically manifesting as increased skin light transparency.

[0030] In some embodiments, the concentration of lysine or its salt in the above-mentioned skin light-transparent agent is not less than 30% (w / v), preferably 30% to 50% (w / v), and more preferably 35% to 40% (w / v).

[0031] In some embodiments, the solvent in the above-mentioned skin light-transparency agent can be deionized water, physiological saline, or phosphate buffer.

[0032] In some embodiments, the aforementioned skin light-transparency agent further includes functional synergistic components. It is understood that these functional synergistic components are not the sole or primary active ingredient of the skin light-transparency agent. The purpose of adding these components is to enhance or stabilize the skin light-transparency effect of lysine or its salts by improving the penetration, action environment, or synergistic optical effects of lysine or its salts in skin tissue. These different mechanisms of action can exist individually or synergistically, thereby making the skin light-transparency effect of lysine or its salts more significant and stable. This application does not specifically limit the type of functional synergistic components. Those skilled in the art can add appropriate types of functional synergistic components according to actual needs, all of which are within the scope of protection of this application. In some embodiments, the aforementioned functional synergistic components include, but are not limited to, one or more of penetration enhancers, water-retaining agents, and synergistic light-transparency agents. Penetration enhancers can be used to improve the entry efficiency or distribution depth of lysine or its salts in skin tissue; water-retaining agents can be used to alleviate or inhibit skin tissue dehydration during the action of lysine or its salts; and synergistic light-transparency agents can participate in the skin tissue refractive index regulation or light scattering inhibition process together with lysine or its salts.

[0033] It is understood that this application does not limit the specific types of the aforementioned penetration enhancers, water-retaining agents, and synergistic brightening agents, and all reagents reported in the prior art that help improve skin transparency are applicable to this application. For example, the aforementioned penetration enhancers may be selected from, but are not limited to, one or more of dimethyl sulfoxide and polyols (e.g., propylene glycol, butylene glycol). The aforementioned water-retaining agents may be selected from, but are not limited to, one or more of glycerin, hyaluronic acid, urea, and hydrophilic polysaccharides (e.g., trehalose, dextran). In some embodiments, the aforementioned synergistic brightening agents may be selected from, but are not limited to, one or more of iohexol, sorbitol, and polyethylene glycol.

[0034] In some embodiments, the concentration of the aforementioned synergistic functional component in the skin light-transparency agent is 1% (w / v) to 15% (w / v). In practical applications, those skilled in the art can adjust the appropriate concentration based on the type of synergistic functional component selected. For example, the concentration of the synergistic functional component in the aforementioned skin light-transparency agent can be 1% (w / v), 2% (w / v), 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 7% (w / v), 8% (w / v), 9% (w / v), 10% (w / v), or a range consisting of any two of the aforementioned values.

[0035] In some embodiments, the light-transparent agent further includes a pharmaceutically or cosmetically acceptable carrier. In some embodiments, the light-transparent agent can be in various dosage forms such as an aqueous solution, gel, cream, or patch.

[0036] The skin light-transparency agent provided in this application can be applied to the surface of detached or living skin tissue. For living skin, the agent can be applied topically to achieve light transparency; for detached skin, it can be applied by immersion. It is understood that this application does not preclude combining the above with other penetration-enhancing methods for light transparency treatment, but the aforementioned light transparency effect can also be achieved without relying on other penetration-enhancing methods.

[0037] Based on this, this application provides the application of the above-mentioned skin light-transparent agent in long-term transparentness of living skin, fluorescent labeling of ex vivo skin tissue cells, and preparation of drugs for adjuvant photodynamic therapy.

[0038] On the other hand, this application also provides a method for phototransparency of living skin tissue, which is for non-therapeutic purposes and includes the following steps: The above-mentioned skin light-transparency agent was applied to bare skin tissue, and after standing, the skin became light-transparent.

[0039] In some embodiments, the method further includes imaging the light-transparent skin, which can increase the contrast, resolution, or depth of the image.

[0040] In some embodiments, the method further includes removing the skin light-transparent agent from the light-transparent skin and then cleaning the skin tissue surface to restore the skin tissue to its original state.

[0041] It should be understood that materials of the same or similar type, model, quality, properties, or function as the reagents and instruments used in the following embodiments can be used to implement this application. Unless otherwise specified, the experimental methods used in the following embodiments are conventional methods. Unless otherwise specified, the materials and reagents used in the following embodiments are commercially available.

[0042] The following are examples and comparative examples: Example 1 This embodiment investigates the effect of L-lysine as an active ingredient in skin light-transparency agents on the light-transparency of isolated skin tissue.

[0043] The skin-transparent agent provided in this embodiment is an aqueous solution of L-lysine at a series of concentrations, which is prepared by fully dissolving L-lysine solid powder in purified water at room temperature. The mass-volume concentrations of L-lysine in the above-mentioned skin-transparent agents are 30% (w / v), 35% (w / v), 40% (w / v), and 50% (w / v), respectively.

[0044] The method for performing light-transparency treatment on isolated skin tissue using the above-mentioned skin light-transparency agent includes the following steps: S1. Select the skin samples from the back of the fixed nude mouse, completely remove the subcutaneous fat and cut them into samples with a length and width of 1cm×1cm as the original state of the ex vivo skin tissue. S2. The above-mentioned isolated skin tissues in their original state were immersed in L-lysine aqueous solutions with a mass-volume ratio of 30% (w / v), 35% (w / v), 40% (w / v), and 50% (w / v) to perform phototransparency treatment.

[0045] The original skin samples from step S1 and the light-transparent skin samples from step S2 (soaked for 30 min and 60 min respectively) were stripped of their surface solution and laid flat on a graduated plate (minimum division 1 mm). The light-transparency effect of the skin samples was observed by taking photographs. The results are as follows: Figure 1 As shown.

[0046] Depend on Figure 1As can be seen, without soaking in the skin light-transparency agent, the isolated mouse skin tissue was cloudy and opaque, and the background scale lines could not be displayed. After treating the isolated mouse skin with the skin light-transparency agent (L-lysine aqueous solution) provided in this embodiment, the isolated skin tissue became transparent, and the previously invisible background scale lines could be observed. This indicates that the skin light-transparency agent provided in this embodiment can effectively improve the light transparency of skin tissue. Specifically, when the mass-volume ratio concentration of L-lysine in the skin light-transparency agent was 30% (w / v), the light transparency rate of the isolated skin was slightly slower and the light transparency effect was limited. When the mass-volume ratio concentration of L-lysine was 50% (w / v), the isolated skin showed slight dehydration and shrinkage during the light transparency treatment. When the mass-volume ratio concentration of L-lysine was 35% (w / v) and 40% (w / v), the isolated skin tissue achieved excellent light transparency while maintaining good tissue morphology.

[0047] Furthermore, following the experimental procedures described above, isolated skin tissue in its original state was immersed in L-lysine aqueous solutions with concentrations of 30% (w / v), 35% (w / v), 40% (w / v), and 50% (w / v) for 50 min, respectively. Every 10 min, the isolated skin tissue was removed from the L-lysine aqueous solution, the surface was wiped dry, and the tissue was placed on a US military standard resolution plate. Imaging was performed using an industrial camera to evaluate the effect of the L-lysine aqueous solution on improving the optical transparency resolution of isolated skin tissue. The results are as follows: Figure 2 , Figure 3 As shown.

[0048] Depend on Figure 2 , Figure 3 It can be seen that, compared with 30% (w / v) and 50% (w / v) L-lysine aqueous solutions, 35% (w / v) and 40% (w / v) L-lysine aqueous solutions can significantly improve the optical transparency resolution of isolated skin tissue during the optical transparency treatment process. Specifically, after optical transparency treatment of isolated skin tissue with 35% (w / v) L-lysine aqueous solution for 10 minutes, the line pairs of Group 2 Element 1 on the US military standard resolution board, which were previously not visible, can be observed (resolution of 2.24 lp / mm). After optical transparency treatment for 30 minutes, the resolution can reach 8 lp / mm, showing fast optical transparency rate and excellent optical transparency effect.

[0049] Comparative Example 1 This comparative study investigated the effects of glycerol, sucrose, and hyaluronic acid on the light-transmitting properties of isolated skin tissue. Specifically, the study included the following steps: S1. Select the skin samples from the back of the fixed nude mouse, completely remove the subcutaneous fat and cut them into samples with a length and width of 1cm×1cm as the original state of the ex vivo skin tissue. S2. The ex vivo skin tissue in its original state was immersed in 70% (w / v) glycerol solution (referred to as 70% glycerol), 70% (w / v) sucrose solution (referred to as 70% sucrose), and 30% (w / v) hyaluronic acid solution (referred to as 30% HA) for 60 min, respectively. Every 10 min, the ex vivo skin tissue was removed from the L-lysine aqueous solution, the surface residual solution was wiped dry, and it was placed on a US military standard resolution plate. Imaging was performed using an industrial camera to evaluate the effects of glycerol, sucrose, and hyaluronic acid on improving the light transparency resolution of the ex vivo skin tissue. The results are as follows: Figure 4 As shown.

[0050] Depend on Figure 4 Content (a), Figure 4 As can be seen from content (b), in the group treated with 70% gly for light transparency, the light transparency effect of the ex vivo skin tissue was limited, with a resolution of less than 5 lp / mm, and complete light transparency could not be achieved; in the group treated with 70% sucrose for light transparency, the light transparency resolution of the ex vivo skin tissue was not effectively improved even after a treatment time of 20 min, and the light transparency rate was slow; in the group treated with 30% hyaluronic acid for light transparency, the light transparency resolution of the ex vivo skin tissue was not effectively improved even after a treatment time of 50 min, and the resolution was still less than 4 lp / mm even after a treatment time of 60 min, indicating a slow light transparency rate and poor light transparency effect.

[0051] Example 2 This embodiment investigates the effect of a skin light-transmitting agent based on a lysine-water-retaining synergistic system, consisting of L-lysine and a water-retaining agent (hyaluronic acid), on the light-transmitting effect of isolated skin tissue.

[0052] The skin light-transparency agent based on the lysine-water-retaining synergistic system provided in this embodiment is: a lysine-water-retaining skin light-transparency agent composed of an L-lysine aqueous solution with a concentration of 35% (w / v) and hyaluronic acid of different concentrations; wherein, in the above-mentioned lysine-water-retaining skin light-transparency agent, the mass-volume ratio concentration of L-lysine is 35% (w / v), and the mass-volume ratio concentrations of hyaluronic acid are 5% (w / v) and 10 (w / v), respectively.

[0053] The method for phototransparency treatment of isolated skin tissue using the above-mentioned lysine-water-retaining skin light-transparency agent includes the following steps: S1. Select the skin samples from the back of the fixed nude mouse, completely remove the subcutaneous fat and cut them into samples with a length and width of 1cm×1cm as the original state of the ex vivo skin tissue. S2. The above-mentioned isolated skin tissue in its original state was placed in a 35% (w / v) L-lysine aqueous solution (referred to as 35%lys), a 35% (w / v) hyaluronic acid aqueous solution (referred to as 35%HA), a 35% (w / v) L-lysine + 5% (w / v) hyaluronic acid lysine-hydrating skin light-transmitting agent (referred to as 35%lys+5%HA), and an L-lysine solution. The skin was immersed in a lysine-based, water-retaining skin light-transparency agent (referred to as 35% lys + 10% HA) with a mass-to-volume concentration of 35% (w / v) and hyaluronic acid (10% (w / v)) to achieve light transparency, resulting in transparent ex vivo skin. Every 15 minutes, the ex vivo skin tissue was removed from the skin light-transparency agent, the surface was wiped dry, and the tissue was laid flat on a graduated plate (minimum graduation 1 mm). The light transparency effect of the ex vivo skin was observed using a camera. The results are as follows: Figure 5 As shown.

[0054] Depend on Figure 5 It can be seen that, compared to the treatment groups using only 35% lysine (light-transparency treatment time of 60 min) or only 35% hyaluronic acid (light-transparency treatment time greater than 60 min), the treatment group using 35% lysine + 5% hyaluronic acid can achieve complete light transparency of ex vivo skin tissue in a shorter time (light-transparency treatment time of only 45 min), and can also alleviate the dehydration effect of lysine on skin tissue. This indicates that L-lysine and hyaluronic acid in the lysine-hydrating skin light-transparency agent have a synergistic effect, exerting a water-retention effect while further enhancing the light-transparency effect. Furthermore, as the concentration of hyaluronic acid in the lysine-hydrating skin light-transparency agent increases, the ex vivo skin turns yellow after light-transparency treatment. In practical use, to ensure excellent observation results, the concentration of hyaluronic acid can be appropriately reduced.

[0055] Example 3 This embodiment investigated the effect of L-lysine as an active ingredient in skin light-transparency agents on the light-transparency of living skin tissue. Specifically, it included the following steps: A 35% (w / v) L-lysine aqueous solution was used as a skin light-transparency agent and applied to the skin surface of 8-week-old male nude mice (BALB / c Nude) to perform light-transparency treatment on the living skin tissue. The dermal blood vessels in the same area before and after light-transparency treatment were observed using a camera. The results are as follows: Figure 6As shown.

[0056] Depend on Figure 6 As can be seen, without the application of the skin light-transparency agent, the vascular imaging of nude mouse skin is blurry, and the branch vessels are not clear. After using the skin light-transparency agent provided in this application to treat live skin tissue for light transparency, some branch vessels that were previously invisible can be observed, and the visibility and clarity of the dermal vascular network of the live skin are significantly improved. The above results indicate that the skin light-transparency agent provided in this application, when applied to the surface of live skin tissue, can effectively reduce light scattering of live skin tissue without invasive procedures, significantly improve the light transparency effect of live skin tissue, and improve imaging quality.

[0057] Those skilled in the art will readily understand that the above description is merely a preferred embodiment of this application and is not intended to limit this application. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A biosafe skin light-transparency agent, characterized in that, It contains lysine or its salt as an active ingredient.

2. The skin light-transparent agent according to claim 1, characterized in that, The lysine is L-lysine; and / or, The salt is a hydrochloride, acetate, or aspartate.

3. The skin light-transparent agent according to claim 1 or 2, characterized in that, The concentration of lysine or its salt in the skin light-transmitting agent is not less than 30% (w / v).

4. The skin light-transparent agent according to claim 3, characterized in that, The concentration of lysine or its salt in the skin light-transmitting agent is 30%~50% (w / v).

5. The skin light-transparent agent according to any one of claims 1 to 4, characterized in that, The skin light-transparency agent also includes functional synergistic components; The functional synergistic component is selected from one or more of the following: penetration enhancer, water-retaining agent, and synergistic transparent agent.

6. The skin light-transmitting agent according to claim 5, characterized in that, The penetration enhancer is selected from one or more of dimethyl sulfoxide, propylene glycol, and butanediol; and / or, The water-retaining agent is selected from one or more of glycerin, hyaluronic acid, urea, and hydrophilic polysaccharides; and / or, The synergistic transparentizing agent is selected from one or more of iohexol, sorbitol, and polyethylene glycol.

7. The skin-transparent agent according to claim 5, characterized in that, The concentration of the functional synergistic component in the skin light-transmitting agent is 1% (w / v) to 15% (w / v).

8. The use of a skin light-transparent agent as described in any one of claims 1 to 7 in the long-term transparentness of living skin, the construction of fluorescent labels on ex vivo skin tissue cells, and the preparation of a medicament for adjuvant photodynamic therapy.

9. A method for phototransparency of living skin tissue, characterized in that, Includes the following steps: The skin light-transparent agent according to any one of claims 1 to 7 is applied to bare skin tissue, and after standing, light-transparent skin tissue is obtained.

10. The method for phototransparency of living skin tissue according to claim 9, characterized in that, The method also includes imaging the light-transparent skin tissue.

Images